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Original Article
Ten‑year outcomes of uveal melanoma based on The Cancer Genome
Atlas (TCGA) classification in 1001 cases
Carol L Shields, Eileen L Mayro, Zeynep Bas, Philip W Dockery, Antonio Yaghy, Sara E Lally, Arupa Ganguly1,
Jerry A Shields
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Purpose: To understand the prognostic value of The Cancer Genome Atlas (TCGA) for uveal melanoma
metastasis, using a simplified 4‑category classification, based on tumor DNA. Methods: A retrospective
cohort study of 1001 eyes with uveal melanoma at a single center, categorized according to TCGA as
Group A, B, C, or D (by fine‑needle aspiration biopsy for DNA analysis), and treated with standard
methods, was studied for melanoma‑related metastasis at 5 and 10 years. Results: Of 1001 eyes with uveal
melanoma, the TCGA categories included Group A (n = 486, 49%), B (n = 141, 14%), C (n = 260, 26%),
and D (n = 114, 11%). By comparison, increasing category (A vs. B vs. C vs. D) was associated with features
of older age at presentation (56.8 vs. 52.8 vs. 61.1 vs. 63.5 years, P < 0.001), less often visual acuity of
20/20–20/50 (80% vs. 67% vs. 70% vs. 65%, P = 0.001), tumor location further from the optic disc (P < 0.001)
and foveola (P < 0.001), and greater median tumor basal diameter (10.0 vs. 13.0 vs. 14.0 vs. 16.0 mm,
P < 0.001) and tumor thickness (3.5 vs. 5.2 vs. 6.0 vs. 7.1 mm, P < 0.001). The Kaplan–Meier (5‑year/10‑year)
rate of metastasis was 4%/6% for Group A, 12%/20% for Group B, 33%/49% for Group C, and 60%/not
available for Group D. Conclusion: A simplified 4‑category classification of uveal melanoma using TCGA,
based on tumor DNA, is highly predictive of risk for metastatic disease.
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The Cancer Genome Atlas (TCGA) is an international
collaborative project designed by the National Cancer
Institute’s Center for Cancer Genomics and the National
Human Genome Research Institute for the investigation
of human cancer‑related mutations. This project explored
molecular aberrations on various platforms including histologic
features, chromosome copy numbers, genetic mutations,
expression of RNA, DNA methylation status, proteins,
biochemical pathways, and immune markers for 33 cancer
types, including uveal melanoma.[1‑8] In 2017, Robertson et al.
published TCGA results of 80 eyes with uveal melanoma and
identified four distinct molecular subsets, two associated
with good prognosis (disomy 3 [D3]) and two associated
with poor prognosis (monosomy 3 [M3]).[3] In 2018, Jager
et al. commented on TCGA results for uveal melanoma in an
editorial, indicating the enormity and organization of this
project, and provided clarity to the 4 main prognostic categories
of uveal melanoma as identified by TCGA.[4] They remarked
that these clusters included Group A (D3, disomy 8), Group
B (D3, 8q gain), Group C (M3, 8q gain possible), and Group D
(M3, 8q gain multiple [isochromosome for 8q]).
In 2019, Vichitvejpaisal et al. applied the simplified 4‑group
classification of TCGA to a cohort of 658 patients with uveal
melanoma at a single center and found the 5‑year cumulative
percentage of distant metastasis (odds ratio, OR) at 4% (OR 1.0)
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for Group A, 20% (OR 3.5) for Group B, 33% (OR 11.4) for
Group C, and 63% (OR 26.4) for Group D.[5] Mazloumi et al.
later documented that TCGA classification provided superior
accuracy to the American Joint Committee on Cancer (AJCC)
8th ed.ition categories, subcategories, and stages for 5‑year
prediction of metastasis of uveal melanoma.[7] Herein, we explore
a larger cohort of 1001 cases with a longer follow‑up period using
5‑year and 10‑year Kaplan–Meier analyses to further validate
TCGA in the prediction of uveal melanoma metastasis.

Methods
The medical records of the Ocular Oncology Service at the
Wills Eye Hospital, Thomas Jefferson University, Philadelphia,
Pennsylvania, USA, were retrospectively reviewed for patients
with the clinical diagnosis of uveal melanoma between February
4, 2004 and June 2, 2020, who underwent genetic evaluation and
assessment for The Cancer Genome Atlas (TCGA) classification.
This study was approved by the Institutional Review Board of
Wills Eye Hospital, adhering to the tenets of the Declaration of
Helsinki, and complied with the Health Insurance Portability
and Accountability Act. Informed consent was obtained from
all patients.
This is an open access journal, and articles are distributed under the terms of
the Creative Commons Attribution‑NonCommercial‑ShareAlike 4.0 License,
which allows others to remix, tweak, and build upon the work non‑commercially,
as long as appropriate credit is given and the new creations are licensed under
the identical terms.
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All patients were examined by a trained ocular
oncologist (CLS, SEL, JAS) for clinical confirmation of diagnosis
of uveal melanoma based on indirect ophthalmoscopy with
large detailed fundus drawings and imaging. Ophthalmic
imaging included fundus photography with wide‑angle
imaging, fundus autofluorescence, ultrasonography, optical
coherence tomography (OCT), fluorescein angiography,
indocyanine green angiography, and OCT angiography,
as needed for documentation at the first examination and
subsequent examinations. Those patients who had undergone
genetic testing by fine‑needle aspiration biopsy or open biopsy
with results on the status of chromosomes 3 and 8 were
classified according to TCGA as A, B, C, or D and included
in this study.

univariate analysis at a level of P < 0.05 (age, largest tumor basal
diameter, tumor thickness, distance from the optic disc, distance
from the foveola, location of the tumor epicenter, anterior
margin of the tumor, and posterior margin of the tumor) were
entered into multivariate multiple regression models using
the stepwise Wald method, which further excluded variables
non‑contributory to the fit of the model (P > 0.05). Odds
ratios and 95% confidence intervals were generated for both
univariate and multivariate regression models. Kaplan–Meier
analysis was performed for metastasis (liver metastasis, lung
metastasis, any metastasis) and death from uveal melanoma.
A P value < 0.05 was considered statistically significant for the
results of multivariate multiple regression and Kaplan–Meier
analysis.

Data were recorded at each examination and documented
in patient’s chart. The demographic data included age (years),
sex (male, female), race (Caucasian, African American,
Hispanic, Asian, others/unknown), affected eye (right, left),
and visual acuity (20/20–20/50, 20/60–20/200, 20/400–no light
perception [NLP]).

Results

The tumor features at presentation included tumor location
with distance from the optic disc (millimeters [mm]), distance
from the foveola (mm), largest tumor basal diameter (mm),
tumor thickness (mm), tumor epicenter (choroid, ciliary body,
iris), anterior margin of the tumor (macula, macula to the
equator, equator to ora serrata, ciliary body, iris), and posterior
margin of the tumor (macula, macula to the equator, equator
to ora serrata, ciliary body, iris).
Samples for genetic testing were obtained by fine‑needle
aspiration biopsy (FNAB), performed in the operating room
at the time of uveal melanoma treatment, as described in the
literature.[5] The samples were stored in Hanks’ balanced
salt solution (Gibco, Life Technologies, Grand Island, NY) at
4 degrees Celsius, and DNA analysis was performed using a
DNA Micro Kit (QIAGEN, Valencia, CA).[5]
Primary outcomes included the rate and mean time to
melanoma‑related metastasis and death. Information on
metastasis was gathered through history from the patient and
correspondence from physicians. Information on death was
gathered through history from the family and correspondence
from physicians and family. Metastasis was further stratified
based on the rate of metastasis to the liver, lung, and other
systemic locations. Kaplan–Meier analysis at 1 year, 2 years,
5 years, and 10 years for each outcome of melanoma‑related
metastasis and death as well as metastasis to the liver,
lung, and other systemic locations was stratified by TCGA
classification (Group A vs. Group B vs. Group C vs. Group D).
Additionally, Cox regression analyses to assess competing
risks were performed but did not differ significantly from
Kaplan–Meier analysis in this population.
Statistical analysis was performed using SAS Software
Suite (version 9.4; SAS Institute). Continuous variables
were expressed as mean (median, range). The one‑sample
Shapiro–Wilk test was used to assess the normality of
distribution. A comparison between groups was performed
using the one‑way ANOVA test for continuous variables with
normal distribution and the Kruskal–Wallis test for continuous
variables without normal distribution. A comparison of
categorical variables was performed using the likelihood ratio
Chi‑square test and Fisher’s exact test when indicated. Binary
logistic regression analysis was performed to identify factors
potentially predictive of metastasis and death, which could
act as confounders because of their strong correlation with
the TCGA classification. Variables found to be significant in

There were 1001 consecutive eyes with uveal melanoma
in 999 patients that were sampled for DNA analysis of
chromosomes 3 and 8 at the time of tumor management at the
Ocular Oncology Service at the Wills Eye Hospital at Thomas
Jefferson University, Philadelphia, Pennsylvania USA, over a
22‑year period. Patients with no genetic testing and/or those
with no follow‑up information were not included in this
analysis.
Of all 1001 eyes with uveal melanoma, TCGA categories
included Group A (n = 486, 49%), B (n = 141, 14%),
C (n = 260, 26%), and D (n = 114, 11%). Demographic features
are listed in Table 1. By comparison, increasing category
(A vs. B vs. C vs. D) was associated with older age at presentation
(56.8 vs. 52.8 vs. 61.1 vs. 63.5 years, P < 0.001) and less often
visual acuity of 20/20–20/50 (80% vs. 67% vs. 70% vs. 65%,
P = 0.001). There was no difference in sex, race, or affected eye.
Tumor characteristics are listed in Table 2. By comparison,
increasing category (A vs. B vs. C vs. D) was associated
with tumor location further from the optic disc (P < 0.001)
and foveola (P < 0.001), increasing tumor basal diameter
(10.5 mm vs. 12.7 mm vs. 13.6 mm vs. 15.3 mm, P < 0.001) and
tumor thickness (4.4 mm vs. 6.2 mm vs. 6.7 mm vs. 7.6 mm,
P < 0.001), greater frequency of the anterior margin involving
the ciliary body (13% vs. 28% vs. 32% vs. 41%, P < 0.001),
and less frequency of the posterior margin in the macula
(63% vs. 56% vs. 48% vs. 55%, P < 0.001).
Outcomes for melanoma‑related metastasis and death
are listed in Table 3. Overall mean follow‑up duration was
41.0 months (median 30.6, range < 0.1–184.9), and tumors
with greater TCGA classification had a shorter follow‑up
duration (46.4 vs. 45.0 vs. 32.4 vs. 32.7, P < 0.001).
By comparison, increasing category (A vs. B vs. C vs. D)
was associated with the increased rate of any melanoma
metastasis (3% vs. 9% vs. 20% vs. 46%, P < 0.001), shorter mean
time to any metastasis (37.4 vs. 38.7 vs. 27.7 vs. 21.5, P = 0.009),
and specifically the increased rate of liver metastasis
(2% vs. 9% vs. 20% vs. 46%, P < 0.001), lung metastasis
(<1% vs. 1% vs. 4% vs. 10%, P < 0.001), metastasis to
other systemic locations (bone, brain, breast, intestine,
distant lymph nodes, mesentery, muscle, skin)
(1% vs. 4% vs. 5% vs. 14%, P < 0.001), and melanoma‑related
death (<1% vs. 0% vs. 2% vs. 7%, P = 0.003). By comparison,
increasing specific category was associated with the increased
odds ratio (OR) for any metastasis (A vs. B, OR 2.48 (P = 0.026);
A vs. C, OR 6.21 (P = 0.027); A vs. D, OR 22.25 (P < 0.001))
and for liver metastasis (A vs. B, OR 3.20 (P = 0.026); A vs. C,
OR 7.32 (P = 0.009); A vs. D, OR 25.04 (P < 0.001)). A similar
increasing risk (A vs. D) was observed for lung metastasis (OR
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Table 1: Ten‑Year Outcomes of Uveal Melanoma Based on The Cancer Genome Atlas (TCGA) Classification in 1001 Cases.
Patient demographics
Patient Demographics

TCGA Class

Total Population

A
(n=486) [n (%)]

B
(n=141) [n (%)]

C
(n=260) [n (%)]

D
(n=114) [n (%)]

P

56.8 (58.0,
10.0 - 90.0)

52.8 (54.0,
13.0 - 83.0)

61.1 (62.5,
12.0 - 88.0)

63.5 (64.0,
28.0 - 94.0)

<0.001

58.1 (59.0,
10.0 - 94.0)

Male

266 (55)

72 (51)

121 (47)

57 (50)

0.194

516 (52)

Female

220 (45)

69 (49)

139 (53)

57 (50)

472 (97)

130 (92)

251 (97)

112 (98)

African American

0 (0)

2 (1)

0 (0)

0 (0)

Hispanic

10 (2)

3 (2)

5 (2)

2 (2)

20 (2)

Asian

1 (<1)

3 (2)

1 (<1)

0 (0)

5 (<1)

Other/unknown

3 (1)

3 (2)

3 (1)

0 (0)

9 (1)

Right

249 (51)

77 (55)

143 (55)

60 (53)

Left

237 (49)

64 (45)

117 (45)

54 (47)

20/20 - 20/50

389 (80)

94 (67)

182 (70)

74 (65)

20/60 - 20/200
20/400 - NLP

55 (11)
42 (9)

29 (21)
18 (13)

53 (20)
25 (10)

28 (25)
12 (11)

(n=1001) [n (%)]

Age
Mean (years)
(median, range)
Sex
485 (48)

Race
Caucasian

0.088

965 (96)
2 (<1)

Affected eye
0.760

529 (53)
472 (47)

Visual Acuity
0.001

739 (74)
165 (16)
97 (10)

Bold values indicate significant P. TCGA=The Cancer Genome Atlas; NLP=No light perception

Table 2: Ten‑Year Outcomes of Uveal Melanoma Based on The Cancer Genome Atlas (TCGA) Classification in 1001 Cases.
Tumor features
Tumor Features

TCGA Class

Total Population

A
(n=486) [n (%)]

B
(n=141) [n (%)]

C
(n=260) [n (%)]

D
(n=114) [n (%)]

P

Distance to optic disc (mm)
[mean (median, range)]

3.9
(3.0, 0.0 - 20.0)

4.7
(4.0, 0.0 - 18.0)

5.5
(5.0, 0.0 - 17.0)

4.9
(5.0, 0.0 - 18.0)

<0.001

4.5
(3.5, 0.0 - 20.0)

Distance to foveola (mm)
[mean (median, range)]

3.6
(2.3, 0.0 - 18.4)

4.1
(3.3, 0.0 - 15.0)

5.4
(4.0, 0.0 - 18.0)

4.7
(3.0, 0.0 - 17.0)

<0.001

4.3
(3.0, 0.0 - 18.4)

Largest basal diameter (mm)
[mean (median, range)]

10.5
(10.0, 1.0 - 22.0)

12.7
(13.0, 2.0 - 22.0)

13.6
(14.0, 2.0 - 24.0)

15.3
(16.0, 6.0 - 24.0)

<0.001

12.1
(12.0, 1.0 - 24.0)

Thickness (mm)
[mean (median, range)]

4.4
(3.5, 1.0 - 14.0)

6.2
(5.2, 1.3 - 15.0)

6.7
(6.0, 0.7 - 16.0)

7.6
(7.1, 2.1 - 20.4)

<0.001

5.6
(4.7, 0.7 - 20.4)

0.008

913 (91)

(n=1001) [n (%)]

Tumor epicenter
Choroid

457 (94)

126 (89)

227 (87)

103 (90)

Ciliary body

20 (4)

11 (8)

26 (10)

11 (10)

68 (7)

Iris

9 (2)

4 (3)

7 (3)

0 (0)

20 (2)

Anterior margin
Macula

<0.001

32 (7)

9 (6)

6 (2)

4 (4)

Macula to equator

245 (50)

40 (28)

64 (25)

22 (19)

371 (37)

51 (5)

Equator to ora serrata

131 (27)

44 (31)

81 (31)

38 (33)

294 (29)

Ciliary body

62 (13)

40 (28)

82 (32)

47 (41)

231 (23)

Iris

16 (3)

8 (6)

27 (10)

3 (3)

54 (5)

Macula

305 (63)

79 (56)

124 (48)

63 (55)

Macula to equator

156 (32)

54 (38)

115 (44)

48 (42)

373 (37)

Equator to ora serrata

10 (2)

2 (1)

12 (5)

3 (3)

27 (3)

Ciliary body
Iris

7 (1)
8 (2)

2 (1)
4 (3)

5 (2)
4 (2)

0 (0)
0 (0)

14 (1)
16 (2)

Posterior margin

Bold values indicate significant P. TCGA=The Cancer Genome Atlas

<0.001

571 (57)

48.0
(48.0, 27.2 - 68.8)

2 (<1)

48.2
(53.9, 0.5 - 81.0)

5 (1)

28.4
(28.4, 28.4 - 28.4)

1 (<1)

30.2
(22.2, 0.5 - 65.7)

10 (2)

37.4
(40.2, 0.5 - 81.0)

14 (3)

46.4
(40.1, <0.1 - 161.0)

A
(n=486)
[n (%)]

0.0
(0.0, 0.0 - 0.0)

0 (0)

42.8
(50.7, 6.9 - 65.9)

5 (4)

47.4
(47.4, 17.5 - 77.3)

2 (1)

38.9
(38.3, 1.1 - 77.3)

12 (9)

38.7
(38.3, 1.1 - 77.3)

12 (9)

45.0
(33.9, 0.1 - 184.9)

B
(n=141)
[n (%)]

47.4
(46.0, 38.2 - 59.4)

4 (2)

41.7
(41.8, 13.6 - 73.7)

13 (5)

31.5
(25.1, 1.3 - 65.7)

10 (4)

26.7
(18.7, 0.2 - 85.6)

51 (20)

27.7
(19.1, 0.2 - 85.6)

53 (20)

32.4
(23.9, 0.1 - 173.1)

C
(n=260)
[n (%)]

D
(n=114)
[n (%)]

26.5
(24.3, 3.5 - 50.5)

8 (7)

35.3
(35.2, 3.6 - 72.3)

16 (14)

36.8
(37.5, 5.6 - 72.3)

11 (10)

21.9
(18.0, 0.0 - 107.2)

52 (46)

21.5
(18.0, 0.0 - 107.2)

52 (46)

32.7
(28.0, 0.0 - 117.4)

TCGA Class

26.2
(19.5, 0.0 - 107.2)

0.032

A vs. B: na
A vs. C: 2.26 (0.36 - 14.07)
A vs. D: 9.65 (1.67 - 55.73)
---

---

A vs. B: 1.98 (0.53 - 7.37)
A vs. C: 2.10 (0.67 - 6.57)
A vs. D: 7.30 (2.39 - 22.25)

---

A vs. B: 4.91 (0.44 - 55.23)
A vs. C: 11.50 (1.43 - 92.32)
A vs. D: 34.75 (4.40 - 274.59)

-0.634
0.003
0.097

0.263

0.659
0.709
<0.001

0.896

35.5
(38.3, 3.5 - 68.8)

14 (1)

40.2
(43.4, 0.5 - 81.0)

39 (4)

34.8
(32.9, 1.3 - 77.3)

24 (2)

125 (12)

0.026
0.009
<0.001

A vs. B: 3.20 (1.32 - 7.74)
A vs. C: 7.32 (3.55 - 15.07)
A vs. D: 25.04 (11.81 - 53.11)

0.615
0.047
<0.001

27.3
(19.9, 0.0 - 107.2)

0.009

---

---

131 (13)

0.026
0.027
<0.001

A vs. B: 2.48 (1.11-5.56)
A vs. C: 6.21 (3.32 - 11.62)
A vs. D: 22.25 (11.54 - 42.90)

41.0
(30.6, <0.1 - 184.9)

(n=1001)
[n (%)]

<0.001

P

---

Odds Ratio (95%
Confidence Interval)

Total Population

Indian Journal of Ophthalmology

Bold values indicate significant P. UM = Uveal melanoma, NA= not available. *Sites of other metastasis include bone, brain, breast, intestine, distant lymph nodes, mesentery, muscle, skin

Mean time to death
(months)
(median, range)

Death from UM
metastasis

Mean time to
metastasis (months)
(median, range)

Other metastasis*

Mean time to
metastasis (months)
(median, range)

Lung metastasis

Mean time to
metastasis (months)
(median, range)

Liver metastasis

Mean time to
metastasis (months)
(median, range)

Metastasis

Follow-up (months)
(median, range)

Outcomes

Table 3. Ten-Year Outcomes of Uveal Melanoma Based on The Cancer Genome Atlas (TCGA) Classification in 1001 Cases. Outcomes.
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34.75, P < 0.001) and metastasis to other locations (OR 7.30,
P < 0.001).

single nucleotide polymorphisms, and others; proteome
characterization centers for the identification of cancer‑specific
proteins; data coordinating centers for the collection and
transfer of data to public databases; cancer genomics hub for
storage, cataloging, and access to information; and genome data
analysis centers for the development of informatics tools for
processing data across the entire genome.[2] This unprecedented
effort was then made available for public access, providing
researchers the opportunity to evaluate this data.

Kaplan–Meier analysis of outcomes of metastasis and
death is listed in Table 4 [Fig. 1]. By comparison, increasing
category (A vs. B vs. C vs. D) was associated with greater
risk for any melanoma‑related metastasis (P < 0.001) at
1‑year (1% vs. 2% vs. 7% vs. 15%), at 2‑years (2% vs. 3%
vs. 15% vs. 36%), at 5‑years (4% vs. 12% vs. 33% vs. 60%), and
at 10‑years (6% vs. 20% vs. 49% vs. not available). A similar
increasing risk for liver (P < 0.001), lung (P < 0.001), and other
metastases as well as melanoma‑related death (P < 0.001) over
time were documented [Table 4 and Fig. 1].

In 2017, Robertson et al. were the first to publish results of
TCGA regarding uveal melanoma in 80 cases.[3] They identified
four molecularly‑distinct groups of uveal melanoma, with two
groups demonstrating favorable prognosis related to disomy
3 (D3) and two groups showing poor prognosis related to
monosomy 3 (M3). Within each of the four groups there
were unique gene alterations, DNA methylation, mRNA
expression levels, and other findings that accounted for
increasing the risk for melanoma metastasis. Jager et al. later
clarified this distinct molecular grouping of uveal melanoma
as A, B, C, and D, whereby the criteria for Group A included
D3 and disomy of chromosome 8, Group B showed D3 and
8q gain, Group C showed M3 and often with 8q gain, and
Group D showed M3 with multiple 8q gains manifesting as
an isochromosome for 8q.[4] The simplicity of this 4‑category

Discussion
The Cancer Genome Atlas (TCGA) has provided a comprehensive
“cancer atlas” through wide‑ranging multi‑platform analyses
of over 30 human cancers, including uveal melanoma.[2]
This project involved a multicenter organization including
tissue source sites for the collection of blood and tissue
samples; biospecimen core resources for coordination
of sample delivery and cataloging; genome sequencing
centers for high‑throughput sequencing and identification
of DNA alterations; cancer genome characterization centers
for description of alterations in miRNA, gene expression,

Table 4: Ten‑Year Outcomes for Uveal Melanoma Based on The Cancer Genome Atlas (TCGA) Classification in 1001 Cases.
Event‑Free Survival Analysis of Metastasis and Death
Event‑Free Survival

TCGA Class

Total Population

A
(n=486) [n (%)]

B
(n=141) [n (%)]

C
(n=260) [n (%)]

D
(n=114) [n (%)]

(n=1001) [n (%)]

1 Year

394 (99)

123 (98)

185 (93)

83 (85)

785 (96)

2 Years

315 (98)

92 (97)

118 (85)

52 (64)

577 (91)

5 Years

160 (96)

40 (88)

41 (67)

12 (40)

254 (82)

10 Years

16 (94)

6 (80)

5 (51)

NA

27 (75)

1 Year

394 (99)

123 (98)

185 (93)

83 (86)

785 (96)

2 Years

315 (98)

92 (97)

118 (85)

52 (65)

577 (91)

5 Years

160 (98)

40 (88)

41 (67)

12 (42)

254 (82)

10 Years

17 (96)

6 (80)

5 (55)

NA

28 (77)

1 Year

394 (100)

123 (100)

195 (99)

91 (99)

801 (>99)

2 Years

316 (100)

91 (>99)

130 (97)

64 (95)

601 (99)

5 Years

161 (99)

41 (99)

42 (93)

13 (76)

257 (96)

10 Years

17 (99)

6 (95)

5 (89)

NA

28 (94)

1 Year

394 (>99)

121 (99)

196 (100)

92 (99)

802 (>99)

2 Years

316 (>99)

91 (99)

131 (99)

64 (93)

604 (99)

5 Years

160 (98)

40 (95)

42 (88)

14 (71)

256 (93)

10 Years

16 (97)

6 (90)

5 (83)

NA

27 (90)

1 Year

394 (100)

123 (100)

196 (100)

92 (99)

802 (>99)

2 Years

316 (100)

92 (100)

131 (100)

66 (96)

604 (99)

5 Years
10 Years

162 (>99)
17 (99)

41 (100)
6 (100)

42 (93)
5 (93)

14 (85)
NA

259 (97)
28 (97)

Overall Metastasis

Liver Metastasis

Lung Metastasis

Other Metastasis*

Death from Uveal Melanoma

TCGA=The Cancer Genome Atlas, NA=not available. *Sites of other metastasis include bone, brain, breast, intestine, distant lymph nodes, mesentery, muscle,
skin
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Figure 1: Kaplan–Meier estimates of metastasis and survival according to The Cancer Genome Atlas (TCGA) classification into Group A, B, C,
or D. With increasing group, there was increasing risk for liver metastasis (P < 0.001), lung metastasis (P < 0.001), any metastasis (P < 0.001),
and death (P < 0.001)

DNA‑based classification scheme provides a straightforward
approach for stratifying uveal melanoma prognosis, as
previous investigations have included complex multiple
factors[9‑14] such as over 50 combinations of DNA alterations
in chromosomes 3, 6, and 8 giving a stepwise, graded
prognosis,[15,16] whereas others have blended in the AJCC
classification[17‑19] with DNA alterations[20,21] further refining
prognosis, and still others have combined DNA alterations
of chromosomes 3 and 8 plus mitotic activity, closed loops,
epithelioid cells, basal tumor diameter, extraocular spread,
and optic disc and ciliary body involvement in the equation
for an all‑inclusive prognosis.[22,23]
In 2019, Vichitvejpaisal et al. validated the 4‑category TCGA
classification in an analysis of 658 cases, demonstrating that
the 5‑year Kaplan–Meier cumulative percentage of distant
metastasis based on DNA results for Group A was 4%, B was
20%, C was 33%, and D was 63%.[5] In that cohort, longer‑term,
10‑year data was not available. In this current analysis, we
explore a larger cohort of 1001 cases of uveal melanoma with
more robust 10‑year Kaplan–Meier outcomes. Based on TCGA
classification using DNA results, we found that the 5‑year
Kaplan–Meier rate of any distant metastasis for Group A
was 4%, B was 12%, C was 33%, and D was 60%, whereas the

10‑year Kaplan–Meier rate of any distant metastasis for Group
A was 6%, B was 20%, C was 49%, and D was not available
due to the small cohort number. The odds ratios for any
distant metastasis (vs. Group A) were 2.48 for Group B, 6.21
for Group C, and 22.25 for Group D. Furthermore, the 10‑year
Kaplan–Meier rates of specific liver metastasis revealed Group
A at 4%, B at 20%, C at 45%, and D not available with odds
ratios for liver metastasis (vs. Group A) at 3.20 for Group B,
7.32 for Group C, and 25.04 for Group D.
Understanding the uveal melanoma prognosis is an
important driver for adjuvant therapies to prevent metastasis.
Before TCGA data were released, a previous study of adjuvant
sunitinib[24] for patients at a high‑risk of metastases, defined
as M3 and 8q gain or M3 and large tumor size[15] or gene
expression profiling of Class 2,[25,26] revealed a better overall
survival in the treatment arm, particularly if the patient was
younger than 60 years of age. Currently, we employ TCGA
classification for high‑risk adjuvant trials, and those that
meet the criteria for Group C or Group D are considered for
adjuvant therapy.
There are limitations to this study including its retrospective
nature and the rarity of uveal melanoma. However, in our practice
of ocular oncology, we specialize in the management of uveal
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melanoma and have offered FNAB for DNA prognostication to
all patients undergoing therapy, with subsequent monitoring
of patient outcomes for decades. When we began our FNAB
program for genetic testing in the mid‑2000s, analysis was
performed only on chromosome 3; thus the data from these
patients could not be incorporated into TCGA as information on
chromosome 8 is required. Nowadays, we sample for multiple
chromosomes and our large cohort of 1001 eyes with uveal
melanoma includes information on chromosomes 3 and 8 and
provides a robust sample for validation of outcomes. Another
limitation of this dataset is that outcomes for metastasis and
death were per report by the patient, family, or physician. We
realize that there can be gaps with this method of information
collection, but this represents “real world” data analysis. Some
metastatic and death events could be under‑reported.

Conclusion
In conclusion, we have updated our database regarding
prognostic classification of uveal melanoma by the 4‑category
TCGA and now provide 10‑year outcomes for any metastasis
and specifically for metastasis to the liver, lung, and other
sites. We have shown that increasing TCGA grouping leads to
a significantly (P < 0.001) increased risk for metastatic events
and death over time. This classification system is practical and
highly predictive of uveal melanoma metastatic risk.
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